7.79

0.89% -0.06

Acrivon Therapeutics Inc (ACRV)

Overview News Price History Financials Discussions Forecast

Acrivon Therapeutics Inc stock is traded at $7.79, with a volume of 13,554. It is down -0.89% in the last 24 hours and up +10.98% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Previous Close:

$7.85

Open:

$7.78

24h Volume:

13,554

Relative Volume:

0.16

Market Cap:

$242.51M

Revenue:

Net Income/Loss:

$-60.39M

P/E Ratio:

-3.1172

EPS:

-2.499

Net Cash Flow:

$-43.93M

1W Performance:

-5.93%

1M Performance:

+10.98%

6M Performance:

-18.87%

1Y Performance:

+35.30%

1-Day Range:

$7.6925

$7.89

1-Week Range:

$7.6925

$8.46

52-Week Range:

$3.19

$11.90

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name

Acrivon Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617-207-8979

Address

480 ARSENAL WAY, SUITE 100, WATERTOWN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ACRV's Discussions on Twitter

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-23	Initiated	BMO Capital Markets	Outperform
Apr-27-23	Initiated	Ladenburg Thalmann	Buy
Apr-20-23	Initiated	H.C. Wainwright	Buy
Dec-12-22	Initiated	Cowen	Outperform
Dec-12-22	Initiated	Jefferies	Buy
Dec-12-22	Initiated	Piper Sandler	Overweight

View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

Oct 30, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World

Oct 30, 2024

Oct 28, 2024

Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa

Oct 28, 2024

Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com India

Oct 28, 2024

Oct 26, 2024

(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 26, 2024

Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews

Oct 26, 2024

Oct 19, 2024

Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World

Oct 19, 2024

Oct 17, 2024

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire

Oct 17, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat

Oct 17, 2024

Oct 16, 2024

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 16, 2024

Oct 15, 2024

(ACRV) Investment Analysis and Advice - Stock Traders Daily

Oct 15, 2024

Oct 12, 2024

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance

Oct 12, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Oct 12, 2024

Oct 11, 2024

Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com

Oct 11, 2024

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire

Oct 11, 2024

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel - The Bakersfield Californian

Oct 11, 2024

Acrivon Therapeutics, Inc. Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Marketscreener.com

Oct 11, 2024

Oct 05, 2024

Trend Tracker for (ACRV) - Stock Traders Daily

Oct 05, 2024

Oct 02, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Bought by Marshall Wace LLP - MarketBeat

Oct 02, 2024

Sep 30, 2024

Perceptive Advisors LLC Acquires 2,353,000 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - MarketBeat

Sep 30, 2024

Sep 28, 2024

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expands By 24.3% - MarketBeat

Sep 28, 2024

Sep 27, 2024

Wall Street SWOT: Acrivon Therapeutics stock shows promise amid oncology challenges - Investing.com

Sep 27, 2024

Sep 24, 2024

The Potential Rise in the Price of ACM Research Inc (ACMR) following insiders activity - Knox Daily

Sep 24, 2024

DRW Securities LLC Invests $287,000 in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World

Sep 24, 2024

Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch

Sep 24, 2024

You might want to take a look at ACM Research Inc (ACMR) now - SETE News

Sep 24, 2024

When the Price of (ACRV) Talks, People Listen - Stock Traders Daily

Sep 24, 2024

Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance

Sep 24, 2024

Benjamin F. Edwards & Company Inc. Has $847,000 Stock Position in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World

Sep 24, 2024

Sep 23, 2024

Ladenburg Thalmann Upgrades Acrivon Therapeutics Inc (ACRV) to a Buy from a Neutral - Knox Daily

Sep 23, 2024

Deeper Dive: Understanding Acrivon Therapeutics Inc (ACRV) Through its Various Ratios - The Dwinnex

Sep 23, 2024

Brighton Jones LLC Makes New Investment in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World

Sep 23, 2024